Prospective validation of the prognostic and predictive impact of uPA/PAI-1 in early breast cancer
{{output}}
Introduction: An emerging challenge in early breast cancer (eBC) is improving risk assessment through the use of biomarkers. Clinical guidelines have recommended urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1.... ...
